Navigation Links
Ocular Therapeutix, Inc. Appoints Two New Board Members

WALTHAM, Mass., Oct. 1 /PRNewswire/ -- Ocular Therapeutix, Inc. announced today the expansion of its board of directors with the appointment of Mr. Daniel Myers and Mr. Bernard Haffey.

Mr. Myers is currently the President, CEO and co-founder of Alimera Sciences, Inc., a biopharmaceutical company that is developing and commercializing prescription ophthalmic pharmaceuticals. Under his leadership, Alimera has raised venture funding totaling approximately $90M. Myers has over 25 years of experience in the ophthalmic pharmaceutical industry in sales, marketing, and general management. "I am pleased to have the opportunity to contribute to the Ocular Therapeutix Board of Directors. The I-ZIP® Ocular Bandage has the potential to be of great benefit to patients in the future," said Myers.

Mr. Haffey was most recently President and CEO of NDO Surgical, a medical technology company dedicated to the development of innovative endoscopic technologies for gastrointestinal diseases. Prior to this position, he joined IntraLase Corp. as Vice President, Business Development. With over 10 years experience in medical technology, Haffey has a proven track record of successfully launching emerging medical technology and medical device companies. Additionally, he has successfully helped three of his former companies through acquisition including NDO Surgical and Intralase. "I am delighted to be joining the world-class team at Ocular Therapeutix and look forward to helping the company achieve world-class business results," said Haffey.

"We are extremely fortunate to add industry veterans such as Bernie and Dan to our board. While Bernie brings commercial leadership and expertise particularly in the refractive and corneal areas, Dan has deep expertise in ophthalmic pharmaceutical and drug delivery. Their addition to our team will be key as we move forward towards commercialization of the I-ZIP bandage in the US and as we build our drug delivery programs," said Amar Sawhney, President and CEO of Ocular Therapeutix. The appointment of Mr. Haffey and Mr. Myers increases the number of Ocular Therapeutix directors to seven. Board members also include Amar Sawhney, Fred Khosravi of Access Closure, Inc., Charles Warden of Versant Ventures, Sam Wu of SV Life Sciences, and Alan Crane of Polaris Ventures.

About Ocular Therapeutix, Inc:

Ocular Therapeutix, Inc. is a privately held company based in Waltham, MA focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology. The company was founded in November 2006. The I-ZIP Adherent Ocular Bandage is CE Mark approved and the I-ZIP Ocular Bandage is under clinical investigation in the United States.

I-ZIP is a registered trademark of Ocular Therapeutix, Inc.

SOURCE Ocular Therapeutix, Inc.

SOURCE Ocular Therapeutix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ISTA Pharmaceuticals Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
2. Study of Lacrisert(R) Dry Eye Insert Published in The Ocular Surface
3. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
4. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
5. VELOCITY Broadcasting Appoints Senior Director of Strategic Business Development
6. Premier Research Appoints Troy W. McCall, Ph.D. as Chief Executive Officer
7. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
8. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
9. NovaRx Appoints Industry Veteran as President and COO
10. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
11. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... to their offering. --> Research and ... of the "Self Administration of High Viscosity ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... convenient way to dispense prescription medications at home, so he invented the patent-pending ... monitor and dispense prescription medications. In doing so, it could help to prevent ...
(Date:11/27/2015)... ... 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% ... More than 3.7 billion people under the age of 50 – or 67% of the ... first global estimates of HSV-1 infection . , "The data shocks us highly!" said ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind challenges ... health and wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular ... experienced by parents and bring advice from parenting experts within their reach. As ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
Breaking Medicine News(10 mins):